comparemela.com

Latest Breaking News On - Tdxd - Page 1 : comparemela.com

HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd

Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.

Evolving testingTreatment strategiesMetastatic colorectal cancerClinical trial data withColorectal cancerHer2 positiveHer2 crcHer2 antibodiesTrastuzumab deruxtecanT dxdDestiny crc01Dose adjustmentDose reductionInterstitial lung diseaseAsco 2023Asco annual meeting

Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Improving outcomesBreast cancerTranslating evidenceClinical practiceYear old woman withMetastatic breast cancerVirginia kaklamaniHer2 positiveHer2 breast cancerInterstitial lung diseaseThp therapyCleopatra trialCleopatra regimenCleopatra studyTrastuzumab deruxtecanT dxd

Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

A key opinion leader in breast cancer management shares insight on the treatment armamentarium for patients with HER2+ disease.

Improving outcomesBreast cancerTranslating evidenceClinical practiceMetastatic breast cancer treatmentMetastatic breast cancerHer2 positiveHer2 breast cancerThp therapyCleopatra regimenTrastuzumab emtansineDestiny breast03Trastuzumab deruxtecanT dxdDestiny breast02Her2climb trial

HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care

Closing out his review of therapy for HER2+ metastatic breast cancer, Kevin Kalinsky, MD, MS, looks toward future evolutions in the treatment landscape.

Kevin kalinskyImproving outcomesBreast cancerTranslating evidenceClinical practiceBreast cancer withLeptomeningeal metastasesFuture directionsMetastatic breast cancerHer2 breast cancerHer2 positiveLeptomeningeal metastasisTucatinib therapyNovel therapyClinical trialsCombination therapy

HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium

Comprehensive insight on the treatment armamentarium currently available to patients with HER2+ metastatic breast cancer and CNS disease.

Improving outcomesBreast cancerTranslating evidenceClinical practiceMetastatic breast cancerHer2 breast cancerHer2 positiveFirst line treatmentFirst line therapyFrontline treatmentThp therapyCleopatra trialCleopatra regimenTrastuzumab deruxtecanT dxdDestiny breast trials

vimarsana © 2020. All Rights Reserved.